RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer

This is a pilot study to evaluate the effects of azeliragon to decrease cardiac toxicity from chemotherapy and the safety of azelirgaon when given with chemotherapy. The Investigators hypothesize that there will be no significant interaction with Azeliragon and chemotherapy and that targeting the RAGE pathway will decrease anthracycline related cardiotoxicity and chemotherapy related cognitive decline.

Trial Details

NCT ID
NCT05256745
Phase
PHASE1 / PHASE2
Sponsor
Georgetown University
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • TTP488
  • ddAC/ddT
  • TC
  • TCHP
  • Chemotherapy regimen that includes ddAC
Locations (sample)
  • Washington D.C., District of Columbia, United States|38.89511,-77.03637
  • Washington D.C., District of Columbia, United States|38.89511,-77.03637
  • Hackensack, New Jersey, United States|40.88593,-74.04347

Key Eligibility Criteria

  • Patients must have clinical or pathologic stage I-III, histologically confirmed breast cancer, with any ER (estrogen-receptor), PR (progesterone re…
  • a. Chemotherapy regimens administered per USPI (United States Prescribing Information) label: i. Dose dense doxorubicin plus cyclophosphamide follo…
  • Patients must have had no prior chemotherapy/radiotherapy/or systemic therapy for early stage breast cancer, or any other malignancy
  • Age ≥18 years.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →